Search Results 91-100 of 17322 for colitis

  1. Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease - Mayo Clinic

    ... ulcerative colitis or Crohn's disease. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

  2. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) - Mayo Clinic

    A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) · Overview.

  3. Health care maintenance in patients with IBD - Mayo Clinic

    Following preventive care recommendations is extremely important in the management of patients with inflammatory bowel disease.

  4. Sulfasalazine (oral route) - Mayo Clinic

    For treatment of ulcerative colitis: For oral dosage form (enteric-coated tablets):. Adults—At first, 500 to 1000 milligrams (mg) every 6 to 8 ...

  5. A Study of the Effect of Vedolizumab in Conjunction with Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis - Mayo Clinic

    A Study of the Effect of Vedolizumab in Conjunction with Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis · Overview · Participation ...

  6. Mayo Clinic Q&A podcast Dr. Faubion IBD

    If you take a look at all forms of inflammatory bowel disease, both Crohn's disease and ulcerative colitis, the incidence has actually been increasing. Narrator ...

  7. Rectal bleeding Causes - Mayo Clinic

    Pseudomembranous colitis (colon inflammation caused by an infection) ... Ulcerative colitis (a type of inflammatory bowel disease). Causes shown here are ...

  8. Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

  9. Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies - Mayo Clinic

    ... ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in ...

  10. A Study to Evaluate Effectiveness and Safety of TD-1473 in Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis with up to 60 weeks of treatment. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...